Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc. (ACRS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2026
Reporting Period: Quarter and six months ended June 30, 2026
This filing serves as a notification that the company issued a press release on August 6, 2026, announcing its financial results for the specified periods. The detailed results are contained in Exhibit 99.1 (Press Release), which is furnished but not deemed "filed" under Section 18 of the Exchange Act.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The following metrics are not present in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: Specific values for these metrics are not available in the filing text provided; they are referenced only as being included in the attached press release (Exhibit 99.1).
Material Changes
The filing text does not provide specific details regarding material changes versus prior comparable periods. It only confirms the issuance of results for the quarter and six months ended June 30, 2026.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These elements, if present, would be located in the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 6, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical or commercial milestones achieved during the quarter ended June 30, 2026.
- Check for any updated guidance or changes in the development timeline for the company's product candidates.
- Confirm the company's cash runway and any recent financing activities mentioned in the full press release.